Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Capital Expenditures (2021 - 2025)

ARS Pharmaceuticals' Capital Expenditures history spans 5 years, with the latest figure at -$5.5 million for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 6445.98% year-over-year to -$5.5 million; the TTM value through Dec 2025 reached $339000.0, down 39.79%, while the annual FY2025 figure was $339000.0, 39.79% down from the prior year.
  • Capital Expenditures for Q3 2025 was -$5.5 million at ARS Pharmaceuticals, down from $5.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.8 million in Q2 2025 and bottomed at -$5.5 million in Q3 2025.
  • The 5-year median for Capital Expenditures is $85500.0 (2021), against an average of $76437.5.
  • The largest YoY upside for Capital Expenditures was 7050.6% in 2025 against a maximum downside of 6445.98% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at -$767000.0 in 2021, then surged by 111.86% to $91000.0 in 2022, then decreased by 7.69% to $84000.0 in 2023, then skyrocketed by 466.67% to $476000.0 in 2024, then plummeted by 1259.87% to -$5.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Capital Expenditures are -$5.5 million (Q3 2025), $5.8 million (Q2 2025), and $91000.0 (Q1 2025).